Voclosporin (ISA247) for plaque psoriasis

The Lancet

Volumn 372, Issue 9642, 2008, Pages 888-889

  Naidoo, Poobalan ^a   Rambiritch, Virendra ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; ISA 247; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VOCLOSPORIN;

FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; PRIORITY JOURNAL; PSORIASIS VULGARIS; RECURRENCE RISK; RISK FACTOR;

EID: 51249124874     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61391-4     Document Type: Letter

References (4)

1. Papp K., Bissonnette R., Rosoph L., et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 371 (2008) 1337-1342
2. Naldi L. The search for effective and safe disease control in psoriasis. Lancet 371 (2008) 1311-1312
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
4. Chaidemenos G.C., Mourellou O., Avgoustinaki N., Papakonstantinou M., Karakatsanis G., and Katsambas A. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol 21 (2007) 1203-1208